الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 167 |  |  |
| | | from | 167 | | |
Abstract
Psoriasis is a common cutaneous inflammatory pathology affecting
2% of the population that results from genetic predisposition as well as
environmental factors.
Psoriasis is a T-cell mediated disease characterized by thickened
epidermis, hyperproliferation and abnormal differentiation of
keratinocytes accompanied by vascular hyperplesia and inflammatory
immune cell infiltrates into psoriatic skin secrete large amounts of
inflammatory cytokines such as interferon (INF)-γ, tumour necrosis
factor (TNF)-α, oncostatin M (OSM), interleukin 12, IL-17, IL-23 and
IL-22.
Interleukin-22 is produced by special immune cell proliferations
including Th22, Th1, Th17 cells; classical and non-classical (NK-22)
cells, NKT cells and lymphoid tissue inducer cells. The main biological
role of IL-22 includes the increase of innate immunity, protection from
damage and enhancement of regeneration.
PASI score is the most commonly used measure to investigate the
severity and coverage of psoriasis, and also for evaluation of the
improvement after therapy. The “PASI concept” was the first measure to
describe the clinical severity and improvement after therapy in patients
with psoriasis.
This study was performed at Menoufia University Hospital to
determine the serum levels of interleukin 22 (IL-22) in psoriatic patients
and to correlate it with PASI score.
The present study included 40 adult psoriatic patients and 20
healthy age and sex-matched adults as control group. Patient group
included 17 females (42.5%) and 23 males (57.5%) their ages ranged from 15 and 77 years with a mean age of 39.70 ±16.68 years. While in
control group there were 11 females (53.3%) and 9 males (46.7%) their
ages ranged from 18 and 69 years with mean age of 33.50± 14.94 years.
Patients and controls were subjected to full history taking thorough
clinical evaluation and blood sampling for measurement of IL-22 serum
levels. PASI scoring system was used for the assessment of severity of
psoriasis in patient group and ELISA technique was used for
measurement of serum IL-22 levels.
There was a statistically non-significance correlation between
serum levels of interleukin 22 and age, sex, smoking and disease
duration.
The current study showed that there was a statistically significant
higher serum levels of interleukin-22 among the psoriasis patients with a
mean value (875.77±107.10) compared to those of the control group with
a mean value (7.13 ±5.56).
There was a statistically non-significant correlation found between
generalized and localized psoriasis and serum levels of interleukin 22.
The present study also showed that there was a statistically
significant correlation between PASI in psoriatic patients and serum
levels of interleukin 22 indicating that the higher serum levels of IL-22
were found in patients with higher PASI score.
There was a statistically significant correlation found between
presence of itching and serum levels of interleukin 22.
There was a statistically significant correlation between the
presence of itching and PASI score.
There was a statistically non-significant correlation between
smoking and psoriasis severity PASI.
There was no statistically significant difference in the serum levels
of IL-22 and the two types of psoriasis (generalized psoriasis and
localized psoriasis). Also there was no statistically significant correlation
between the types of psoriasis and psoriasis area and severity index
(PASI).